Jbf Capital, Inc. Fibrogen Inc Transaction History

Jbf Capital, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$37.97 - $60.16 $535,377 - $848,256	-14,100 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$44.9 - $64.95 $224,500 - $324,750	5,000 Added 54.95%	14,100 $883,000
Q1 2018 May 11, 2018	BUY	$45.35 - $61.65 $412,685 - $561,015	9,100 New	9,100 $420,000

46.8M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $47.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Jbf Capital, Inc., based on Form 13F filings with the SEC.

Stay updated on Jbf Capital, Inc. with notifications on news.